The Valley Desk

NCT06555796 · Interventional trial

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

Overall registry status Active not recruiting

Phase 1

Conditions High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, High-risk Biochemical Recurrence, Non-metastatic Castration-sensitive Prostate Cancer, Prostate Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov